DABRAFENIB
Manner of administration:Oral
Restriction
Indication: Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma
Treatment phase: Initial treatment
Restriction
Indication: Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 120 | # of repeats: 3 | DPMQ: $4,799.35 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tafinlar | |||||
Manner of administration:Oral
Restriction
Indication: Paediatric high grade glioma
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 240 | # of repeats: 3 | DPMQ: $9,489.92 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tafinlar | |||||
Manner of administration:Oral
Restriction
Indication: Paediatric high grade glioma
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 240 | # of repeats: 1 | DPMQ: $9,489.92 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tafinlar | |||||
Manner of administration:Oral
Restriction
Indication: Paediatric low grade glioma
Treatment phase: Initial treatment
Restriction
Indication: Paediatric low grade glioma
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 240 | # of repeats: 3 | DPMQ: $9,489.92 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tafinlar | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17286)
Indication: Stage IV (metastatic) non-small cell lung cancer (NSCLC)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 120 | # of repeats: 5 | DPMQ: $4,799.35 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tafinlar | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17949)
Indication: Unresectable Stage III or Stage IV malignant melanoma
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 120 | # of repeats: 5 | DPMQ: $4,799.35 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tafinlar | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 10157)
Indication: Unresectable Stage III or Stage IV malignant melanoma
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 120 | # of repeats: 3 | DPMQ: $4,799.35 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tafinlar | |||||